Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF - Test2 - elhamkhani - TriplyDB

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

http://www.wikidata.org/entity/Q24298749

about

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease p21-Activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112 The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling Raf family kinases: old dogs have learned new tricks A secretory kinase complex regulates extracellular protein phosphorylation Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Analysis of the genome to personalize therapy for melanoma Complexity in KSR function revealed by Raf inhibitor and KSR structure studies PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Improved survival with vemurafenib in melanoma with BRAF V600E mutation Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations Resistant mechanisms to BRAF inhibitors in melanoma The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Melanoma: oncogenic drivers and the immune system Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Targeting melanoma by small molecules: challenges ahead Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF The dynamic nature of the kinome Melanoma: new insights and new therapies Melanocyte stem cells as potential therapeutics in skin disorders The RASopathies Targeted therapies in development for non-small cell lung cancer Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options Melanoma: from mutations to medicine

P2860

047e38fa5eb0eb5f277fa86683628a7fa3f490b3 36c5c8d3ce7b266726ebb74d4a05f6b41cf44bfd 490bac9edc08ea8ba3aa2626739bce1faa9d7d09 547428e76b3725a26e949ab97beedddae82af6dd eb9cc4b0fce7c3da1d478575528813c9f13bccd1 ebd4203e42107bcccb5988dd977579abe9709a79 f905b2712b430edf9d29ef162da566f4412c66c9

P248

Q21004109-512451A3-C441-4D87-87E4-4CADB40A1196 Q21132689-6A7AC20A-2808-448B-A3D9-9255C33DE69E Q21134717-F79C5036-E374-4A1C-A5C5-4978BBBEF3CC Q21134956-C5A630C3-A682-4675-B686-36B195698FB4 Q21629049-B348C5BD-34BA-4727-84AD-C0B74338BE3B Q24294914-6D97CE12-7EC3-4E50-BFEB-81B9A4B18B0A Q24299821-EDFD444C-582A-41AE-940E-9D668BD14B4C Q24303940-ACF078B8-30FB-48D7-8E7F-3EE79E3CDC2E Q24314807-E2D66E74-3ED2-48CF-A9A5-5B8CF4A34ACC Q24316181-D51513E2-C9F8-4148-9C12-496CCFE0626A Q24323147-F1CA67BA-5DE5-4837-8DF0-90B8F8E6103B Q24594790-1419C827-B0D4-4285-B0BB-5965D748718E Q24597152-1BDFCFB8-729F-4EEF-91BC-08187A337327 Q24601008-49AB09CB-8EFC-4DE1-9405-D39002FB825A Q24603489-A469E9E1-B037-4702-9C64-1D27A3184AB5 Q24606438-AE0C06BD-E18C-4C34-9742-AD3BEDDF6773 Q24615826-F27A5A80-B90A-4416-94B4-9E7D6ED3DCDB Q24629474-5DE31F38-66AD-4A04-ABD4-F2B569689D70 Q24631953-614491D3-79F2-4F24-8359-EB070FE582C8 Q24632064-7FA0F98C-9529-4831-95D6-2853CFB4B746 Q26739717-1928F796-D466-4FC1-B9BB-81AF48A66033 Q26747247-82DF1F48-B7C0-4E2A-ABD2-B7B54B529509 Q26751520-AE982D3D-65C1-4EAC-B655-5CE051425443 Q26771192-3D94AD00-3D73-432E-82D3-E6300D50AD08 Q26775598-660571AA-7D95-43EE-BBE1-7C7DBB0C94BF Q26795510-C74AF282-218E-4E03-824C-055B3E91C39D Q26795609-A61C66FF-FEF3-4767-A7E7-A6FD618D3CD3 Q26795735-DEE2A062-4C84-45F4-9FAF-59F73BCC8A0E Q26799864-2729CF87-51C5-4318-A1B6-C531506C9BCA Q26823978-246D42F7-A7E5-4FE8-8DC9-2721B67E4F3A Q26824310-20074952-BEEA-4C26-817F-4344ED5B4AC6 Q26824642-0E0BDD2D-FE96-4D2E-BE35-5A784E87B852 Q26827212-B8C5F654-531A-4A8B-844F-AA0987BD133F Q26852588-F602A10C-0240-4476-919A-46445BB00D82 Q26853127-BD52AFDA-719D-49A0-A0E4-B31B1641ECCC Q27008330-E9F9C28C-341B-4724-942A-8701CB493009 Q27022142-B743085C-F9CA-46CF-A0CF-122D59300B82 Q27022852-44E3A3EA-B0C5-4347-8019-EF72959252BA Q27023596-D6E50B55-EB16-4003-86EB-3F0A995A2FC6 Q27024061-41CA3D15-BB46-4FFF-B61D-0A1F1244D2F4

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

http://www.wikidata.org/entity/Q24298749

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@ast

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@en

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@en-gb

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@nl

type

label

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@ast

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@en

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@en-gb

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@nl

altLabel

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

@en

prefLabel

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@ast

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@en

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@en-gb

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

@nl

P1433

Q24298749-917D3E80-673D-4445-84B7-06ED4D8EC986

P1476

Q24298749-07967C4C-013E-4C5B-AA8B-4095726DEBF9

P2093

Q24298749-152CA487-65F5-48BB-8885-7C96C7763EF5

Q24298749-43AA8308-5F1A-4868-92BF-CB982F6E2660

Q24298749-82367240-DD9C-43D8-AA32-D0048E791CD7

Q24298749-A21C99AF-BC89-4E1B-B113-FA842FA84691

Q24298749-E618C1AE-E527-4AF8-B4E8-781BEEC047BA

P2860

Q24298749-04EA2CA7-ABBB-4643-900A-2FAD24FE6531

Q24298749-1082F0CE-9834-42EA-A733-E204CBC83BA7

Q24298749-11216430-B10F-49C7-B865-5AD85D7CB144

Q24298749-122E6282-A644-4BEC-A986-1BCD2FF2BAFD

Q24298749-1235A18A-1CE2-428B-B35A-4093F5E49578

Q24298749-12F8EBBC-1667-4EBA-A1FD-1D59B4A222B8

Q24298749-20A7D6FD-A0AE-4523-86CA-F9FEB85DB875

Q24298749-2EB71B85-3691-4882-9BF9-63CE689C7A1C

Q24298749-3104953E-D3E7-4BA1-A110-5A49515FA9AE

Q24298749-37407135-5E9C-4AC0-8650-F4EADCF3FB40

P304

Q24298749-F4E8F085-1153-40E0-A731-CCA2B354916F

P31

Q24298749-31F0922F-C0C0-48C7-BF9A-1C250B60DA9A

P3181

Q24298749-5D09088C-97F5-4E8B-894E-BA027234682F

P356

Q24298749-489EA816-0D1B-4F3A-BD19-07321E63716D

P407

Q24298749-B4FA9B33-899E-4ED0-AFB7-26F841B21A41

P433

Q24298749-E038A260-2C0D-489D-8D33-B31B0C6E2B55

P478

Q24298749-E0531D2C-8735-4FBC-908C-C2BC97E39AB4

P50

Q24298749-1A070543-C30D-4BAA-B9E7-7FF1D4E05271

Q24298749-1F516390-6198-4649-AA68-3DCD1ED2A526

Q24298749-B44E05C3-46D2-4410-B54E-FCE95DAB32AD

Q24298749-C0A342E3-EDB2-4F04-BD83-73D1FAC12E32

Q24298749-D3DECABE-C496-4D68-901A-4045F997A87A

Q24298749-E317E897-880C-4336-8ED6-7224C7E2D76C

P577

Q24298749-51E4A2B1-02FF-41CC-89C3-E813BDC16E64

P5875

Q24298749-E67BBAFC-1D46-422F-A7B8-F6980C537A6E

P698

Q24298749-51E462F2-CFFB-4BCE-91BE-FB0C38CD04EE

P921

Q24298749-7FBF6BAD-12EC-49A8-B19A-644A2D7C80C2

Q24298749-A6FEF52A-5092-4979-81CF-935C580B2C84

P932

Q24298749-54A1E1DF-CD9A-4EF7-8A20-A85997FF2B73

P3181

P356

J.CELL.2009.12.040

P1433

P1476

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

@en

P2093

Arnaud Nourry

http://www.w3.org/2001/XMLSchema#string

Carla Milagre

http://www.w3.org/2001/XMLSchema#string

Ion Niculescu-Duvas

http://www.w3.org/2001/XMLSchema#string

Jahan Hussain

http://www.w3.org/2001/XMLSchema#string

Sonja J Heidorn

http://www.w3.org/2001/XMLSchema#string

P2860

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

A dimerization-dependent mechanism drives RAF catalytic activation.

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

Active Ras induces heterodimerization of cRaf and BRaf

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

Guilty as charged: B-RAF is a human oncogene

P304

209-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

867339

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CELL.2009.12.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Reis-Filho

Nathalie Dhomen

Steven Whittaker

Caroline J Springer

Catrin Pritchard

P577

2010-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41416244

http://www.w3.org/2001/XMLSchema#string

P698

20141835

http://www.w3.org/2001/XMLSchema#string

P921

V-raf-leukemia viral oncogene 1

Braf transforming gene

P932

2872605

http://www.w3.org/2001/XMLSchema#string